Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares were up 1.9% during trading on Friday . The company traded as high as $374.90 and last traded at $372.06, with a volume of 626,998 shares trading hands. The stock had previously closed at $365.27.

A number of research analysts have recently issued reports on the company. Robert W. Baird reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, May 16th. Vetr raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $429.64 price objective on the stock in a research note on Monday, June 13th. Leerink Swann reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, April 9th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 30th. Finally, Chardan Capital reaffirmed a “sell” rating and set a $325.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, March 25th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $508.32.

The company has a market capitalization of $38.98 billion and a price-to-earnings ratio of 59.27. The company has a 50 day moving average price of $369.76 and a 200-day moving average price of $399.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $2.57 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.58 by $0.01. During the same quarter in the prior year, the firm posted $2.88 EPS. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Regeneron Pharmaceuticals’s revenue for the quarter was up 38.0% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals Inc. will post $10.80 earnings per share for the current year.

In other news, EVP Plew Daniel P. Van sold 4,413 shares of the stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $385.77, for a total transaction of $1,702,403.01. Following the transaction, the executive vice president now directly owns 11,381 shares in the company, valued at approximately $4,390,448.37. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 1,000 shares of the stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $396.64, for a total transaction of $396,640.00. Following the transaction, the director now owns 40,500 shares in the company, valued at $16,063,920. The disclosure for this sale can be found here.

A number of hedge funds have bought and sold shares of REGN. Ameritas Investment Partners Inc. increased its stake in Regeneron Pharmaceuticals by 1.0% in the fourth quarter. Ameritas Investment Partners Inc. now owns 3,170 shares of the biopharmaceutical company’s stock worth $1,721,000 after buying an additional 32 shares during the period. Brown Advisory Inc. increased its stake in Regeneron Pharmaceuticals by 3.1% in the fourth quarter. Brown Advisory Inc. now owns 1,920 shares of the biopharmaceutical company’s stock worth $1,042,000 after buying an additional 58 shares during the period. Financial Counselors Inc. increased its stake in Regeneron Pharmaceuticals by 5.3% in the fourth quarter. Financial Counselors Inc. now owns 1,846 shares of the biopharmaceutical company’s stock worth $1,002,000 after buying an additional 93 shares during the period. Mutual of America Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,657 shares of the biopharmaceutical company’s stock worth $4,700,000 after buying an additional 93 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,072 shares of the biopharmaceutical company’s stock worth $2,753,000 after buying an additional 104 shares during the period.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.